Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
Providence Health & Services
Thomas Jefferson University
University of Chicago
Indiana University
King Saud University
University of Chicago
University of Chicago
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Icahn School of Medicine at Mount Sinai
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
Washington University School of Medicine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
University of Texas Southwestern Medical Center
Case Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
University of Leipzig
Roswell Park Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)